The efficacy and role of adagrasib: Why is it a new hope in the treatment of lung cancer?

Adagrasib is a KRAS G12C inhibitor that currently shows great potential as a targeted therapy in the treatment of non-small cell lung cancer (NSCLC) . KRAS gene mutations, especially KRAS G12C mutations, play a crucial role in various cancers, especially lung cancer. This mutation occurs in a high proportion of lung cancer patients and is closely related to tumor malignancy and treatment resistance. It has long been considered a difficult target to target. The emergence of adagrasib has changed this situation and brought new hope to patients with KRAS G12C mutations.

The mechanism of action of adagrasib is very unique. It irreversibly binds to the KRAS G12C mutant protein and converts it from an active state to an inactive state, thereby inhibiting downstream signaling pathways (such as MAPK and PI3K-AKT pathways), thereby preventing the proliferation and growth of tumor cells. This type of targeted therapy is more targeted and selective than traditional chemotherapy drugs, thus reducing damage to normal cells and reducing the occurrence of side effects.

In clinical trials, adagrasib showed significant efficacy. For example, in the KRYSTAL-1 trial for patients with advanced non-small cell lung cancer with KRAS G12C mutations, the objective response rate (ORR) of adagrasib reached 45%, and the disease control rate after treatment also showed good results. These research results show that adagrasib can not only effectively control the progression of tumors, but also improve the survival of patients, especially when traditional treatments are ineffective, bringing new hope to patients.

In addition, adagrasib has also shown potential in the treatment of drug-resistant lung cancer. It can still maintain a certain efficacy and delay the progression of the disease after treatment in some patients. Therefore, as a precise targeted drug, adagrasib is undoubtedly a major breakthrough in the field of lung cancer treatment, bringing more treatment options to patients with KRAS G12C mutations.

Reference materials：https://www.krazati.com/